Palvella Q1 net loss $15.8M; cash $261.9M after $230M equity raise; NDA on track H2 2026

PALVELLA THERAPEUTICS, INC.

2026-Q1 EPS reported -$1.20 vs consensus -$0.95 ▼ miss (-26.2%)

Net loss $15.8M ($1.20/share) vs $8.2M ($0.74) in Q1 2025; R&D spend $9.3M up from $4.1M.
Cash, cash equivalents & short-term investments $261.9M as of Mar 31, following $230M oversubscribed equity offering in Feb 2026.
FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic LMs; NDA submission on track for H2 2026.
Phase 3 SELVA study positive topline results; Phase 2 LOTU initiated; Phase 3 for cutaneous VMs and Phase 2 for DSAP planned H2 2026.
Appointed Jennifer McDonough (SVP Market Access) and Kent Taylor (SVP Sales) to strengthen pre-launch commercialization team.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PALVELLA THERAPEUTICS, INC. reported financial results for the first quarter ending March 31, 2026.

Period: the first quarter ending March 31, 2026
Result: reported results

Exact text from the filing

announced its financial results for the quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-210605

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.